Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets

Core Viewpoint - Oculis Holding AG is hosting an R&D Day to provide updates on its late-stage clinical candidates and future development strategies, emphasizing its commitment to addressing unmet medical needs in ophthalmic and neuro-ophthalmic diseases [1][2]. Group 1: Event Details - The R&D Day will take place on April 15, 2025, from 10:00 AM to 12:00 PM ET at the Intercontinental New York Barclay hotel, with options for in-person and virtual attendance [1]. - The event will include presentations from key opinion leaders and a live Q&A session following the formal presentations [2][3]. Group 2: Clinical Pipeline Updates - Oculis will provide updates on three innovative late-stage clinical candidates: OCS-01 for diabetic macular edema (DME), Licaminlimab (OCS-02) for dry eye disease (DED), and Privosegtor (OCS-05) for acute optic neuritis [5][6]. - Enrollment for the Phase 3 DIAMOND trials of OCS-01 has been completed with over 800 patients, and topline data is expected in Q2 2026 [6]. - The development plan for Licaminlimab (OCS-02) aims to adopt a genotype-based personalized approach in DED, with a Phase 2/3 study anticipated to start in the second half of 2025 [6]. Group 3: Future Development Plans - Oculis will announce two new programs utilizing Privosegtor (OCS-05) for treating non-arteritic anterior ischemic optic neuritis (NAION) and for managing acute relapses in multiple sclerosis (MS) patients [6]. - The company is focused on maximizing resources and driving value through its portfolio prioritization strategy [2]. Group 4: Upcoming Investor Meeting - An investor meeting will be held in Iceland on April 29, 2025, where Oculis management and ophthalmology experts will discuss the late-stage pipeline [4].